Anzeige
Erschienen in:
28.09.2019 | Original Article
“Hairy Cell Leukemia (HCL): ‘Real World’ Outcome”
Erschienen in: Indian Journal of Hematology and Blood Transfusion | Ausgabe 2/2020
Einloggen, um Zugang zu erhaltenAbstract
HCL is an uncommon B cell lympho-proliferative disorder with high remission rates. There is paucity of data on the long-term outcome of HCL from India. We retrospectively collected data from individual case records of patients with HCL who were treated in Cancer Institute, Chennai from January 2001 until January 2018. Sixteen patients were diagnosed with HCL and were treated with cladribine (81%), interferon (13%) and one patient received only best supportive care (6%). All the treated patients achieved complete response. More than half of the patients developed febrile neutropenia but there were no treatment related mortality. The 5-year DFS was 77% and 5-year OS was 80%. Relapse of disease was seen in 27%. HCL is a curable malignancy with high remission rates and survival comparable to patient treated in west.